Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Share:
Related AGN
Viking Global Liked AIG, Google, Actavis, Illumina And Cheniere Energy Last Quarter
John Paulson Continues To Bet On Health Care And TV
Actavis Stock - A Must Have For Long-Term Investors (GuruFocus)
Related VRX
Who's The Next Big Pharma Acquisition?
Valeant, Actavis Neck And Neck With Bowel Disorder Drugs
Top Biotech Stock Illumina Hunts For Breakout Gene (Investor's Business Daily)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...